BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16619536)

  • 1. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.
    Cory AH; Chen J; Cory JG
    Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
    Cory AH; Somerville L; Cory JG
    Anticancer Res; 2005; 25(1A):101-6. PubMed ID: 15816525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
    Cory AH; Cory JG
    Anticancer Res; 2002; 22(6C):3805-9. PubMed ID: 12552998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells.
    Somerville L; Cory JG
    Anticancer Res; 2000; 20(5B):3347-55. PubMed ID: 11131634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells.
    He AW; Cory JG
    Oncol Res; 1998; 10(9):455-64. PubMed ID: 10223621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappaB activation.
    Cory AH; Cory JG
    Anticancer Res; 2001; 21(6A):3807-11. PubMed ID: 11911251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.
    Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P
    J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
    Orue A; Chavez V; Strasberg-Rieber M; Rieber M
    BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L1210 cells.
    He AW; Cory JG
    Int J Oncol; 1999 May; 14(5):891-5. PubMed ID: 10200338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
    Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
    Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
    Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
    Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
    Wang T; Lee K; Rehman A; Daoud SS
    Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors.
    Somerville L; Cory JG
    Anticancer Res; 1999; 19(2A):1021-6. PubMed ID: 10368649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc.
    Farhadi E; Safa M; Sharifi AM; Bashash D
    Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
    Hall JG; Cory AH; Hickerson DH; Cory JG
    Anticancer Res; 2001; 21(1A):173-80. PubMed ID: 11299731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
    Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.